The research results on the mechanism of action indicated thatthe combination therapysignificantly downregulate the expression levels of key proteins CXCL12 and CXCR4 in a mouse model of liver fibrosis (Figures 6K–M). The gene discussed is CXCR4; the disease is Hepatic fibrosis.